Table 3. OS of patients with vulvar cancer in univariate and multivariate analysis. Nodal involvement was not included in the multivariate analysis since it is an integral part of the FIGO-staging.
| Parameter | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| 3-years OS | p-value | Comparison | HR (95% CI) | p-value | ||
| SII | 0.001 | ≤866.4 vs. >866.4 | 1.99 (1.15–3.46) | 0.014 | ||
| ≤866.4 | 71.1% | |||||
| >866.4 | 54.1% | |||||
| Age (yr) | 0.004 | ≤69.0 vs. >69.0 | 1.88 (1.03–3.42) | 0.039 | ||
| ≤69.0 | 73.0% | |||||
| >69.0 | 53.6% | |||||
| FIGO-stage | <0.001 | I–II vs. III–IV | 3.45 (1.96–6.08) | <0.001 | ||
| I–II | 78.3% | |||||
| III–IV | 38.2% | |||||
| ECOG PS | 0.488 | 0 vs. 1 vs. 2 vs. 3 | 1.09 (0.79–1.50) | 0.619 | ||
| 0 | 68.7% | |||||
| 1 | 61.6% | |||||
| 2 | 57.1% | |||||
| 3 | 51.4% | |||||
| Grading | 0.560 | |||||
| G1 | 74.9% | |||||
| G2–3 | 61.0% | |||||
| Nodal involvement | <0.001 | |||||
| N0 | 81.5% | |||||
| N1 | 42.2% | |||||
| CRP (mg/dL) | 0.264 | |||||
| <0.5 | 59.4% | |||||
| ≥0.5 | 47.0% | |||||
CI, confidence interval; CRP, C-reactive protein; ECOG PS, Eastern Cooperative Oncology Group performance status; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; OS, overall survival; SII, systemic immune-inflammatory index.